Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- SPECIAL REPORT: The key to Alzheimers on February 21, 2019 at 7:31 am
Could exercise really be the key to preventing Alzheimer’s? NewsCenter’s Beret Leone takes us to the University of Minnesota to discover why they believe so. Abundant sunshine under high pressure toda... […]
- Obituary: Bernice Betty Ritter on February 18, 2019 at 3:05 pm
Bill passed away in 2000 and Bernice moved back to Great Falls until Alzheimers forced her to go into assisted living. To read the complete obituary and share condolences, visit the Schnider ... […]
- Alzheimers/dementia caregivers support group to meet on February 18, 2019 at 6:59 am
OWATONNA — The next Afternoon Support Group for Caregivers assisting people with Alzheimer’s or another dementia will be Tuesday, Feb. 19 from 2:30-3:30 p.m. at the Owatonna Public Library, 105 N Elm ... […]
- Oregon Researchers Seeking Patients With Early Signs Of Alzheimer's on February 18, 2019 at 5:54 am
Dr. William Burke goes over a PET brain scan Tuesday, Aug. 14, 2018, at Banner Alzheimers Institute in Phoenix. Matt York Originally published on February 17, 2019 11:53 am A Portland memory center is ... […]
- Whangārei man completes North Island trek, reaches fundraising goal for Alzheimers Northland on February 15, 2019 at 12:00 pm
The feat of walking the entire length of the North Island for charity is still sinking in for Whangārei man Dean Raynel. The community corrections probation officer set off from Cape Reinga on Decembe... […]
- Alzheimer's study emphasize lowering blood pressure and good dental health to reduce risk on February 14, 2019 at 2:41 pm
Eighty-nine thousand people in South Carolina, alone, are living with Alzheimers and over the next six years that number is expected to jump by 35 percent, according to the Alzheimer's Association. Al... […]
- Chili cookoff event benefiting Alzheimers research set for Saturday on February 13, 2019 at 2:31 pm
The biggest local chili party of the year is coming up this weekend in Fayetteville. The 14th annual Chilirhea chili cook-off is set for Saturday, Feb. 16 at the Washington County Fairgrounds. The eve... […]
- Researchers identify novel molecular mechanism involved in Alzheimer's on February 12, 2019 at 11:47 pm
The findings are published in the current issue of the Journal of Clinical Investigation. Alzheimers is such a devastating disease and currently there is no cure or effective therapy, said Tao Ma, Ph. ... […]
- Alzheimer's Disease Biomarkers Market to Be at Forefront by 2026 on February 11, 2019 at 10:26 pm
Symptoms of the disease are memory loss and mild confusion, often termed as dementia. View Report: https://www.transparencymarketresearch.com/alzheimers-disease-biomarkers-market.html These symptoms a... […]
via Bing News